跳至內容

羅非昔布

維基百科,自由的百科全書
羅非昔布
臨床資料
懷孕分級
  • : C
給藥途徑口服
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度93%
血漿蛋白結合率87%
藥物代謝hepatic
生物半衰期17 hours
排泄途徑biliary/renal
識別資訊
  • 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one
CAS號162011-90-7  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.230.077 編輯維基數據鏈接
化學資訊
化學式C17H14O4S
摩爾質量314.36 g·mol−1
3D模型(JSmol英語JSmol
  • O=C2OCC(=C2\c1ccccc1)\c3ccc(cc3)S(=O)(=O)C
  • InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3 checkY
  • Key:RZJQGNCSTQAWON-UHFFFAOYSA-N checkY

羅非昔布羅非考昔(英語:Rofecoxib/ˌrɒfɪˈkɒksɪb/)商品名VioxxCeoxxCeeoxx。是一種非甾體類抗炎藥NSAID),由默克公司製造、出售。美國食品藥品監督管理局(FDA)於1999年5月20日批准上市,用以治療骨關節炎急性疼痛痛經

由於發現到長期且高劑量用藥有增加心臟病的風險[1][2],默克公司於2004年9月30日起從市場撤回此藥。

合成

[編輯]
羅非昔布的合成[3]

註腳

[編輯]
  1. ^ 偉克適致死 藥廠賠10億. [2017-02-26]. (原始內容存檔於2017-09-12). 
  2. ^ 食品藥物釣愚:《釣愚:操縱與欺騙的經濟學》選摘(3)-食安|藥物|釣愚:操縱與欺騙的經濟學-風傳媒-喬治.艾克羅夫, 羅伯.席勒. [2017-02-26]. (原始內容存檔於2017-04-23). 
  3. ^ Vioxxlawyer.org. Vioxxlawyer.org. [4 January 2015]. (原始內容存檔於2015年1月5日). 

參考文獻

[編輯]
  • FDA (2005). "Summary minutes for the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee." Published on the internet, March 2005. Link頁面存檔備份,存於互聯網檔案館
  • Fitzgerald GA, Coxibs and Cardiovascular Disease, N Engl J Med 2004;351(17): 1709–1711. PMID 15470192.
  • Grassley CE (15 Oct 2004). Grassley questions Merck about communication with the FDA on Vioxx. Press Release.
  • Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (published online; see also Merck response below)
  • Karha J and Topol EJ. The sad story of Vioxx, and what we should learn from it頁面存檔備份,存於互聯網檔案館Cleve Clin J Med 2004; 71(12):933-939. PMID 15641522
  • Michaels, D. (June 2005) DOUBT Is Their Product Archive.is存檔,存檔日期2006-03-21, Scientific American, 292 (6).
  • Merck & Co., (5 Nov 2004). Response to Article by Juni et al. Published in The Lancet on Nov. 5. Press Release.
  • Merck & Co (30 Sep 2004) Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Press release [1].
  • D. M. Mukherjee, S. E. Nissen, and E. J. Topol, "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 186 (2001): 954–959.
  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352(11):1081-91. PMID 15713945
  • Okie, S (2005) "Raising the safety bar--the FDA's coxib meeting." N Engl J Med. 2005 Mar 31;352(13):1283-5. PMID 15800221.
  • Leleti Rajender Reddy, Corey EJ. Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to chronic human toxicity Tetrahedron Lett 2005, 46: 927. doi:10.1016/j.tetlet.2004.12.055
  • Swan SK et al., Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet. Annals of Int Med 2000; 133:1–9
  • Targum, SL. (1 Feb. 2001) Review of cardiovascular safety database. FDA memorandum. [2]頁面存檔備份,存於互聯網檔案館
  • Wolfe, MM et al., Gastrointestinal Toxicity of Nonsteroidal Anti-anflamattory Drugs, New England Journal of Medicine. 1999; 340; 1888-98.

外部連結

[編輯]